01
Actor registration
Economic-operator registration and SRN logic.
EUD–01 · EUDAMED question analysis
EUDAMED R&D Questions: what your team may not be asking before 28 May 2026.
EUDAMED is often treated as a compliance database. For R&D and strategy teams, the sharper question is different: what becomes newly visible, comparable, delayed, exposed or commercially relevant once the information environment around medical devices changes?
FILE 01 · Regulatory trigger
What changes on 28 May 2026.
The European Commission states that the first four EUDAMED modules become mandatory from 28 May 2026: Actor registration, UDI/Devices registration, Notified Bodies and Certificates, and Market Surveillance.
The strategic relevance is not limited to registration. Once actors, devices, certificates and market-surveillance activity move into a more structured European information environment, R&D, regulatory, quality and commercial teams need better questions than a checklist normally provides.
02
UDI/Devices
Device data, Basic UDI-DI and registration visibility.
03
NBs & Certificates
Notified-body and certificate information.
04
Market Surveillance
Regulatory visibility beyond initial registration.
Official source basis: European Commission EUDAMED overview and module pages, including the notice that the first four modules become mandatory from 28 May 2026. See European Commission EUDAMED overview, mandatory use notice, Actor module, and UDI/Devices module.
FILE 02 · Known compliance versus useful ignorance
The compliance question is not the strategic question.
The expected question is: what do we need to register? The nescimus question is: what does registration make visible that changes the research, product or competitive frame?
That distinction matters. A checklist can help a team execute known obligations. A Non-Consensus Question Analysis looks at what may remain unasked because the team is already operating inside a familiar regulatory, product or data model.
EUDAMED creates a concentrated occasion for this work because it touches actors, device data, certificate information and market-surveillance visibility at the same time.
FILE 03 · Information environment
What EUDAMED may make legible.
Structured visibility changes behaviour. When actors, UDI/device information, certificates and surveillance data become easier to search, compare or interpret, they may become more than administrative records.
They can become signals: supplier patterns, certificate dependencies, portfolio assumptions, registration delays, claim boundaries, notified-body exposure, surveillance themes and product-category hesitation. The commercial question is not whether every signal is public today. The question is which internal assumptions should be checked before that visibility becomes normal.
FILE 04 · Method fit
Why this belongs on nescimus, not in a standard regulatory memo.
A regulatory memo answers within the known frame. nescimus is useful when the frame itself may be too narrow.
The output is not a legal opinion and not a submission plan. It is a structured set of questions that can be escalated to R&D, Regulatory Affairs, Quality, Legal, Product Strategy or Commercial. The value is in finding the questions that would otherwise remain outside the meeting agenda.
FILE 05 · Non-Consensus questions
Questions that may deserve escalation before execution starts.
- Which product assumptions become visible once device registration and certificate information move into a structured EU environment?
- Which legacy devices may create strategic exposure before the internal portfolio view has been updated?
- Which market-surveillance signals could competitors interpret before the commercial team does?
- Which product categories sit closer to MDR or IVDR relevance than current internal language suggests?
- Which registration fields may become competitive signals rather than mere administrative entries?
- Which supplier, notified-body or certificate dependencies become newly legible?
- Which R&D projects become more valuable because competitors focus only on compliance execution?
- Which R&D projects become less attractive because EUDAMED increases traceability or comparability?
- Which internal owner is missing for the question: R&D, Regulatory, Quality, Legal, Strategy or Commercial?
- Which product claims could invite new demarcation scrutiny once adjacent data becomes easier to read?
- Which unanswered questions should be escalated before registration becomes an execution task?
- Which opportunity appears only because the industry is treating EUDAMED as a burden rather than an information shift?
FILE 06 · Buying triggers
When the €1,970 analysis makes commercial sense.
Regulatory execution is starting
The team is preparing registration work, but the strategic consequences have not been mapped.
Portfolio assumptions are old
Legacy devices, product claims or category boundaries may not match the new visibility environment.
Multiple functions own fragments
R&D, Regulatory, Quality and Commercial each see part of the picture, but no one owns the question set.
The deadline is close
A fixed-price external analysis can identify questions before internal execution absorbs all attention.
This analysis does not constitute legal, regulatory or notified-body advice. It is a structured question analysis for R&D, strategy, product and regulatory-facing teams.
Single fixed fee
€1,970net · plus VAT where applicable
A document that can pay for itself with one redirected research direction.
- Immediate Stripe checkout
- 10-page structured PDF deliverable
- 10–15 Non-Consensus questions, derived & classified
- Clustering by technical and economic leverage
- Prioritisation by differentiation potential
- Zoom briefing & one revision round
FILE 08 · FAQ
Before you commission the EUDAMED analysis.
Q.01Is this EUDAMED regulatory advice?+
No. The analysis is not legal, regulatory or notified-body advice. It is a structured question analysis for R&D, product, strategy and regulatory-facing teams.
Q.02Why does EUDAMED matter for R&D?+
Because EUDAMED changes the information environment around actors, devices, certificates and market surveillance. That can affect product assumptions, portfolio choices and competitive interpretation.
Q.03What do we receive?+
You receive a structured 10-page PDF with 10 to 15 Non-Consensus questions, derivation, classification, clustering and prioritisation by differentiation potential.
Q.04How fast is delivery?+
Delivery follows within 3 to 5 business days from the Zoom briefing.
Q.05Who should commission this?+
R&D directors, CTOs, heads of innovation, product strategy teams and regulatory-facing teams with medical device, IVD or pharma-adjacent exposure.
Pay now. The questions take it from there.
Immediate Stripe checkout for the fixed-fee analysis. After payment, the Zoom briefing defines the dimension set. Delivery follows within 3–5 business days from the Zoom briefing.